Fresenius SE & Co. KGaA

FRE

DE0005785604

Healthcare Facilities & Services

Market Closed - Xetra Other stock markets 11:35:12 2024-05-03 am EDT			5-day change	1st Jan Change
27.95 ^EUR	-0.07%		+2.72%	-0.43%

May. 03	European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower	MT
May. 03	FRESENIUS SE : Buy rating from Barclays	ZD

FRESENIUS SE : Barclays reiterates its Buy rating

April 22, 2024 at 05:11 am EDT

Barclays analyst Hassan Al-Wakeel maintains his Buy rating on the stock. The target price remains set at EUR 35.

Latest news about Fresenius SE & Co. KGaA

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower	May. 03	MT
FRESENIUS SE : Buy rating from Barclays	May. 03	ZD
FRESENIUS SE : Jefferies remains its Buy rating	May. 03	ZD
FRESENIUS SE : Receives a Buy rating from Berenberg	May. 03	ZD
Fresenius to Sell 67% of Vamed's Rehabilitation Business to PAI Partners	May. 03	MT
PAI Mid-Market Fund SCSp. managed by PAI Partners agreed to acquire 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA.	May. 01	CI
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading	Apr. 29	MT
FRESENIUS SE : Jefferies reiterates its Buy rating	Apr. 26	ZD
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 24	MT
FRESENIUS SE : Warburg Research reiterates its Buy rating	Apr. 24	ZD
FRESENIUS SE : Goldman Sachs sticks Neutral	Apr. 23	ZD
Verme family with other shareholders completed the acquisition of additional 70% stake in Clinica Ricardo Palma S.A. from Fresenius SE & Co. KGaA.	Apr. 22	CI
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	Apr. 22	MT
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading	Apr. 22	MT
FRESENIUS SE : Receives a Buy rating from Jefferies	Apr. 22	ZD
Barclays reads 'Overweight' for Fresenius SE - Target 35 Euro	Apr. 22	DP
FRESENIUS SE : Barclays reiterates its Buy rating	Apr. 22	ZD
FRESENIUS SE : Berenberg keeps its Buy rating	Apr. 22	ZD
Positive trend of FMC and Fresenius continues	Apr. 22	DP
FRESENIUS SE : Gets a Neutral rating from JP Morgan	Apr. 18	ZD
Lauterbach wants to press ahead with hospital reform despite differences	Apr. 17	DP
State report warns of risks in hospital reform	Apr. 17	DP
FRESENIUS SE : Deutsche Bank maintains a Buy rating	Apr. 17	ZD
Warnings against cutbacks in hospital reform	Apr. 17	DP
Federal and state governments to discuss hospital reform again	Apr. 17	DP

Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - dialysis treatment (46.9%; Fresenius Medical Care): sales of equipment for hemodialysis, pediatric dialysis, peritoneal dialysis, dialysis services, etc.; - hospital administration and engineering (34.1%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (19%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (43.8%), North America (39.4%), Asia/Pacific (10.1%), Latin America (5.4%) and Africa (1.3%).

Sector

Healthcare Facilities & Services

Calendar

2024-05-07 - Q1 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

FRESENIUS : A good ending does not allow for extreme optimism in 2024

February 22, 2024 at 07:42 am EST

More Strategies

Ratings for Fresenius SE & Co. KGaA

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

27.95 EUR

Average target price

36.22 EUR

Spread / Average Target

+29.58%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
FRESENIUS SE & CO. KGAA	-0.43%	16.96B
HCA HEALTHCARE, INC.	+13.70%	81.4B
CVS HEALTH CORPORATION	-29.20%	70.18B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+9.72%	29.08B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-11.43%	16.97B
QUEST DIAGNOSTICS INCORPORATED	-0.31%	15.26B
FRESENIUS MEDICAL CARE AG	+3.42%	12.41B
PURE HEALTH HOLDING	-30.70%	11.95B
REDE D'OR SÃO LUIZ S.A.	-6.75%	11.93B
NATERA, INC.	+54.82%	11.85B

Other Healthcare Facilities & Services

Fresenius SE & Co. KGaA

Equities

FRE

DE0005785604

Healthcare Facilities & Services

FRESENIUS SE : Barclays reiterates its Buy rating

Latest news about Fresenius SE & Co. KGaA

Chart Fresenius SE & Co. KGaA

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Fresenius SE & Co. KGaA

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Healthcare Facilities & Services